SPY329.89+3.23 0.99%
DIA266.29+0.81 0.31%
IXIC11,190.15+185.28 1.68%

Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome

FDA to Allow an Additional Higher Dose Level in the Single Ascending Dose Portion (Formerly, Part A) of the Study – - New Preclinical Repeat-Dose Data Support Company Plans to Evaluate Multiple Ascending Dose

· 10/07/2020 07:01

FDA to Allow an Additional Higher Dose Level in the Single Ascending Dose Portion (Formerly, Part A) of the Study –

- New Preclinical Repeat-Dose Data Support Company Plans to Evaluate Multiple Ascending Dose Levels in MONARCH, Subject to FDA Review -

- Enrollment and Dosing in MONARCH is Ongoing; Preliminary Data Still Anticipated in 2021 -